Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
Conditions
Interventions
Vibegron
Locations
6
United States
Children's Hospital of Orange County
Orange, California, United States
Nemours Childrens Health, Jacksonville
Jacksonville, Florida, United States
Wichita Urology Group
Wichita, Kansas, United States
Childrens Hospital New Orleans
New Orleans, Louisiana, United States
Albany Medical College
Albany, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Start Date
October 12, 2022
Primary Completion Date
January 1, 2027
Completion Date
September 1, 2027
Last Updated
July 3, 2024
NCT01565694
NCT02526979
NCT01981954
NCT01539707
NCT04452838
NCT03168828
Lead Sponsor
Urovant Sciences GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions